Frequently Asked Questions
The global monoclonal antibody custom service market was valued at USD 0.5 Billion in 2022.
The monoclonal antibody custom service market is expected to grow at a CAGR of 10.1% between 2023 and 2030, reaching USD 0.98 Billion in 2030.
Rat custom monoclonal antibody is the leading segment by product types, holding over 48% share in terms of value in 2022.
The research & academic laboratories segment governs the global demand for monoclonal antibody custom service, holding a massive share of over 38% in 2022.
The rabbit custom monoclonal antibody segment will post the highest CAGR in the projected period.
Asia Pacific is fueling the rapid growth of the monoclonal antibody custom service industry, with an over one-third share in 2022.
Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, LifeSpan BioSciences Inc, and Abmart are the top market players. Other major players include Creative Diagnostics, Kaneka Eurogentec S.A., Labcorp Drug Development, and GenScript.
The major market drivers are the increasing demand for personalized and targeted therapies and advancements in antibody engineering technologies.
The major market restraints are the high costs associated with custom antibody development and the stringent quality assurance and regulatory compliance requirements.
The major market opportunities of the monoclonal antibody custom service industry include the growing focus on rare diseases and orphan indications and the potential for collaborations and partnerships between pharmaceutical companies and custom service providers.